---
layout: default
title: Abacavir Sulfate Dolutegravir Sodium Lamivudine
parent: Model Prediction Only (L5)
nav_order: 37
evidence_level: L5
indication_count: 0
---

# Abacavir Sulfate Dolutegravir Sodium Lamivudine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE: No Predicted Indications (Insufficient Data)

## One-Sentence Summary

Abacavir + Dolutegravir + Lamivudine is a three-in-one fixed-dose antiretroviral combination (brand name Triumeq), originally used for HIV-1 infection treatment.
In this Evidence Pack, **TxGNN has not generated any new indication predictions**, and this combination drug currently has **no approval record on the Taiwan market**, resulting in lack of data foundation for most assessment fields.
Before filling key data gaps (package insert warnings, MOA, prediction results), **it is recommended to Hold** further drug repurposing assessment.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | HIV-1 infection (per international standard knowledge; this Pack does not provide Taiwan package insert data) |
| Predicted New Indication | None (TxGNN did not output any repurposing candidates in this run) |
| TxGNN Prediction Score | Not applicable |
| Evidence Level | Cannot be determined (no predictions, no clinical trials, no literature) |
| US Market Status | Not marketed (no approval record found in Taiwan drug database) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

The `predicted_indications` field in the current Evidence Pack is empty; the TxGNN model did not output any drug repurposing candidates for this combination drug, making **mechanistic linkage analysis or indication appropriateness assessment not feasible**.

Based on available background information, this combination consists of three fixed-ratio components:

- **Abacavir** (ABC): Nucleoside reverse transcriptase inhibitor (NRTI), requires metabolic activation to carbovir triphosphate before competitively inhibiting HIV-1 reverse transcriptase
- **Dolutegravir** (DTG): Integrase strand transfer inhibitor (INSTI), blocks HIV-1 DNA integration into the host genome
- **Lamivudine** (3TC): NRTI with concurrent HBV activity, inhibits both HBV and HIV-1 reverse transcriptase

The three components act on different targets in the HIV-1 replication cycle, exerting synergistic antiviral effects. Should TxGNN generate predictions for individual components in future runs (especially lamivudine's HBV activity), HBV-related indication extension possibilities would merit priority evaluation.

---

## Data Gap Summary

The current Evidence Pack contains the following two critical data gaps that must be filled before assessment can proceed:

| Gap ID | Gap Item | Severity | Impact | Remediation |
|--------|----------|----------|--------|-------------|
| DG001 | Taiwan package insert warnings / contraindications | Blocking | Cannot proceed to safety initial review | Download and parse the package insert PDF from FDA website |
| DG002 | Mechanism of Action (MOA) | High | Limits mechanistic-link analysis | Query the DrugBank API |

---

## US Market Information

This drug has no approval record found in the Taiwan drug database, making it impossible to list authorization information.

> Note: This three-in-one combination (Abacavir + Dolutegravir + Lamivudine) is approved in the United States under the brand name **Triumeq** (NDA 206708) for HIV-1 infection in adults and children ≥40 kg. If there is clinical need in Taiwan, reference may be made to US FDA approval information and the original package insert.

---

## Safety Considerations

> Safety data (warnings, contraindications, drug interactions) in this Evidence Pack are currently unavailable. Please consult the original package insert and US FDA-approved labeling (Triumeq Prescribing Information) for complete safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN did not output any repurposing candidates, combined with no approval record on the Taiwan market and Blocking-level safety data gaps, the current baseline conditions for drug repurposing assessment are not present.

**To proceed, the following is needed:**

- [ ] **Re-run TxGNN predictions**: Confirm whether the model has established knowledge graph nodes for individual components (abacavir, dolutegravir, lamivudine) and separately generated prediction candidates
- [ ] **Fill MOA data gap (DG002)**: Obtain DrugBank ID and complete mechanism description via DrugBank API as the foundation for mechanistic linkage analysis
- [ ] **Fill safety data gap (DG001)**: Download and parse TFDA package insert PDF (if application has been filed) or substitute with US FDA-approved labeling to complete S1 safety initial review
- [ ] **Confirm applicable assessment unit**: Evaluate whether assessment should proceed on the combination drug as a whole or on individual components (especially lamivudine) as separate drug repurposing assessment subjects

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

